JP2024522820A - 2-アリールベンゾイミダゾールの治療上有効な経口投与 - Google Patents
2-アリールベンゾイミダゾールの治療上有効な経口投与 Download PDFInfo
- Publication number
- JP2024522820A JP2024522820A JP2023578189A JP2023578189A JP2024522820A JP 2024522820 A JP2024522820 A JP 2024522820A JP 2023578189 A JP2023578189 A JP 2023578189A JP 2023578189 A JP2023578189 A JP 2023578189A JP 2024522820 A JP2024522820 A JP 2024522820A
- Authority
- JP
- Japan
- Prior art keywords
- tqs
- administered
- salt
- dose
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211636P | 2021-06-17 | 2021-06-17 | |
| US63/211,636 | 2021-06-17 | ||
| US202263300551P | 2022-01-18 | 2022-01-18 | |
| US63/300,551 | 2022-01-18 | ||
| PCT/US2022/034012 WO2022266455A1 (en) | 2021-06-17 | 2022-06-17 | Therapeutically effective oral administration of a 2 arylbenzimidazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522820A true JP2024522820A (ja) | 2024-06-21 |
| JP2024522820A5 JP2024522820A5 (cg-RX-API-DMAC7.html) | 2025-06-25 |
Family
ID=84527631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578189A Pending JP2024522820A (ja) | 2021-06-17 | 2022-06-17 | 2-アリールベンゾイミダゾールの治療上有効な経口投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20240307356A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355326A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024522820A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022266455A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202416960A (zh) * | 2022-06-17 | 2024-05-01 | 美商特朗奎斯治療股份有限公司 | 2-芳基苯并咪唑化合物之調配物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016061190A1 (en) * | 2014-10-14 | 2016-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| JP2018537507A (ja) * | 2015-12-15 | 2018-12-20 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティThe Board of Trustees of the Leland Stanford Junior University | 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240316008A1 (en) * | 2020-06-22 | 2024-09-26 | Tranquis Therapeutics, Inc. | Treatment of systemic immune activation syndromes |
-
2022
- 2022-06-17 EP EP22825909.9A patent/EP4355326A4/en active Pending
- 2022-06-17 US US18/571,177 patent/US20240307356A1/en not_active Abandoned
- 2022-06-17 JP JP2023578189A patent/JP2024522820A/ja active Pending
- 2022-06-17 WO PCT/US2022/034012 patent/WO2022266455A1/en not_active Ceased
-
2025
- 2025-01-13 US US19/019,406 patent/US20250281462A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016061190A1 (en) * | 2014-10-14 | 2016-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| JP2018537507A (ja) * | 2015-12-15 | 2018-12-20 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティThe Board of Trustees of the Leland Stanford Junior University | 加齢に関連する認知障害及び神経炎症を予防及び/又は治療する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4355326A4 (en) | 2025-04-23 |
| WO2022266455A1 (en) | 2022-12-22 |
| US20250281462A1 (en) | 2025-09-11 |
| US20240307356A1 (en) | 2024-09-19 |
| EP4355326A1 (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60028754T2 (de) | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin | |
| DE69426984T2 (de) | Arzneizubereitung | |
| US7022345B2 (en) | Oral solid pharmaceutical formulations with pH-dependent multiphasic release | |
| ES2596291T3 (es) | Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt | |
| EP4159216A1 (en) | Compositions for treating myelofibrosis | |
| JP7578585B2 (ja) | 骨髄線維症の血小板数非依存的処置方法 | |
| EP2694037B1 (en) | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | |
| PL201274B1 (pl) | Lek przeciwnowotworowy | |
| JP2000515555A (ja) | 医薬組成物 | |
| EP3785698B1 (en) | Edaravone pharmaceutical composition | |
| BR112014011981B1 (pt) | FORMULAgOES FARMACEUTICAS SOLIDAS ORAIS, SEUS PROCESSOS DE PREPARAgAO E USOS | |
| US20240374516A1 (en) | Ready to use oral pharmaceutical suspension of dasatinib | |
| BRPI0812432B1 (pt) | Extrusados, seu uso, e medicamento | |
| US20120141586A1 (en) | Thrombin receptor antagonist and clopidogrel fixed dose tablet | |
| US20250281462A1 (en) | Therapeutically effective oral administration of a 2 arylbenzimidazole | |
| CA2985379A1 (en) | Micronized pharmaceutical compositions for treatment of angiogenisis conditions | |
| EP3993809B1 (en) | System for enhancing therapeutic compliance of the anti-cancer compound e7766 | |
| EP3700531B1 (en) | Dosage regimen of paliperidone palmitate extended-release injectable suspension | |
| EP3386516A1 (en) | Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof | |
| WO2020048449A1 (zh) | 包含1,3,5-三嗪衍生物或其盐的固体药物组合物 | |
| JP2021512140A (ja) | 肝細胞癌の治療のための併用療法 | |
| CN117794531A (zh) | 2-芳基苯并咪唑的治疗上有效的口服给药 | |
| WO2023281404A1 (en) | Controlled release injectable cariprazine formulation | |
| CN106176616B (zh) | 兽用水溶性乙氧酰胺苯甲酯纳米粉、制备方法及应用 | |
| CN103845333A (zh) | 阿伐那非新用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250617 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250617 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20260128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260520 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260520 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260721 |